• Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics (RAPP), sold 276,513 common shares on May 7-8.
• Sales priced at USD 40.12 per share on May 7, USD 40.31 per share on May 8.
• Direct holdings fell to 6,432,715 shares following transactions.
• Separate indirect stake of 969,218 shares reported as held by Third Rock Ventures VI, L.P.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-217092), on May 11, 2026, and is solely responsible for the information contained therein.